More health plans want to pay for drugs based on patient outcomes UncategorizedSeptember 15, 2016Kyle Denton
Lilly’s Trulicity joins pay-for-performance trend with Harvard Pilgrim deal UncategorizedSeptember 15, 2016Kyle Denton
‘Pay For Performance’ Drug Plans Could Impact Biopharma’s R&D Priorities UncategorizedSeptember 15, 2016Kyle Denton
Novartis defies naysayers with newfangled pay-for-performance deals on Entresto UncategorizedSeptember 15, 2016Kyle Denton
More Insurers Want to Tie Pharma Payments to How Effective Drugs Are UncategorizedSeptember 15, 2016Kyle Denton